Literature DB >> 7564117

Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients.

P Fioretto1, M W Steffes, M J Mihatsch, E H Strøm, D E Sutherland, M Mauer.   

Abstract

Five years of normoglycemia following pancreas transplantation (PT) does not ameliorate glomerular lesions in patients with their own kidneys and with long-term insulin-dependent diabetes (IDDM) (Lancet 342:1193, 1993). All these patients received cyclosporine (CsA) as part of their immunosuppression. Here we examined the relationship of CsA dose and blood levels to the presence and severity of CsA-associated renal lesions and changes in renal function in these PT patients. Renal biopsies were taken before (0) and two and five years after PT from 13 non-uremic IDDM patients and were compared with baseline and five year biopsies from 10 IDDM controls (C). CsA dose was reduced from 10 +/- 3 mg/kg/day in the first month to 5 +/- 2 in the fifth year post-PT. Creatinine clearance (CCr) decreased by 34% at one year post-PT and was stable thereafter, and did not change in C. The decline in CCr from 0 to one year was related to CsA blood levels and dose (P < 0.005) at one year. Cortical interstitial volume fraction [Vv(Int/Cortex)], the index of tubular atrophy, and % sclerotic glomeruli increased significantly from 0 to five years post-PT (P < 0.005, 0.01 and 0.001, respectively), but did not change in C. There was no significant change from 0 to two years post-PT in these lesions, while there was a clear progression from two to five years. Mean CsA dose and blood levels in the first year post-PT correlated with the increase (delta) in Vv(Int/Cortex) at five years (P < 0.05 for both).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7564117     DOI: 10.1038/ki.1995.318

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  8 in total

Review 1.  Lessons learned from more than 1,000 pancreas transplants at a single institution.

Authors:  D E Sutherland; R W Gruessner; D L Dunn; A J Matas; A Humar; R Kandaswamy; S M Mauer; W R Kennedy; F C Goetz; R P Robertson; A C Gruessner; J S Najarian
Journal:  Ann Surg       Date:  2001-04       Impact factor: 12.969

2.  Tacrolimus and cyclosporine nephrotoxicity in native kidneys of pancreas transplant recipients.

Authors:  Paola Fioretto; Behzad Najafian; David E R Sutherland; Michael Mauer
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

3.  Pancreas transplantation and reversal of diabetic nephropathy lesions.

Authors:  Michael Mauer; Paola Fioretto
Journal:  Med Clin North Am       Date:  2012-12-07       Impact factor: 5.456

4.  The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007.

Authors:  P Fioretto; M L Caramori; M Mauer
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

Review 5.  Histopathology of diabetic nephropathy.

Authors:  Paola Fioretto; Michael Mauer
Journal:  Semin Nephrol       Date:  2007-03       Impact factor: 5.299

Review 6.  Simultaneous pancreas-kidney transplantation: The role in the treatment of type 1 diabetes and end-stage renal disease.

Authors:  Alex T Jiang; Neal Rowe; Alp Sener; Patrick Luke
Journal:  Can Urol Assoc J       Date:  2014-03       Impact factor: 1.862

Review 7.  Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients.

Authors:  Eric Thervet; Frank Martinez; Christophe Legendre
Journal:  Drug Saf       Date:  2004       Impact factor: 5.228

Review 8.  Sirolimus therapy following early cyclosporine withdrawal in transplant patients: mechanisms of action and clinical results.

Authors:  Eric Thervet
Journal:  Int J Nanomedicine       Date:  2006
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.